NIH Keeps Harassment Tip Line Form Alive for Another Round
Published Date: 6/16/2026
Notice
Summary
The NIH wants to keep their Extramural Harassment Web Form active so people working with NIH grants can safely report harassment. They’re asking the public to share thoughts by July 16, 2026, but no changes or costs are involved—just a smooth continuation. This helps keep NIH’s research community respectful and safe!
Analyzed Economic Effects
1 provisions identified: 0 benefits, 1 costs, 0 mixed.
NIH Harassment Reporting Requirement for Grantees
If your institution receives NIH grant funds, the Authorized Organization Representative must notify NIH through a secure Harassment Web Form when a PD/PI or other Senior/Key personnel are removed or disciplined for harassment, bullying, retaliation, or hostile working conditions. Notifications must be submitted within 30 days and include the AOR's name, the individual's name, a description of the concerns, actions taken, and any anticipated impact on the NIH-funded award; NIH requests OMB approval for 3 years and estimates an annualized burden of 60 hours across 240 private sector respondents (about 15 minutes per response).
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-15565, Proposed Collection; 60-Day Comment Request, Data Use Certification for the NIH Brain Development Cohorts (NBDC) Data Hub, (National Institute on Drug Abuse)
In compliance with the requirement of the Paperwork Reduction Act of 1995 to provide opportunity for public comment on proposed data collection projects, the National Institute on Drug Abuse (NIDA) will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval. The purpose of this revision is to update instructions for the Research Data Use Statement and the Progress Report, and to add new instructions for attesting to National Institute of Standards & Technology (NIST) security compliance, and for a Project Close-out at the time of project completion. Burden levels remain unchanged.
2026-14981, Government Owned Invention Available for License: Nucleophosmin 1 (NPM1) Mutation-Specific T Cell Receptors for Targeted Treatment of Acute Myeloid Leukemia (AML)
The government has developed special T cell receptors that can target a tough type of blood cancer called acute myeloid leukemia (AML), especially in patients with a specific genetic marker. These new receptors promise safer, more precise treatment with fewer side effects than current options. Researchers and companies can now license this invention to help bring this exciting therapy to patients faster.
2026-14980, Government Owned Invention Available for License: Pigment Epithelium-Derived Factor Peptides and Their Use for Treating Retinal Degeneration
The National Eye Institute has a cool new invention using special peptides to help protect eyes from inherited diseases like retinitis pigmentosa, which causes vision loss for over 100,000 Americans. They’re looking for partners to help develop easy-to-use eyedrops or gene therapy to slow down or stop this eye damage. This could bring hope and new treatments to many people with few options, and interested parties can start talking to the NIH now!
2026-14966, Government-Owned Inventions; Availability for Licensing
The National Institutes of Health is offering a new Ebola vaccine invention for companies to license and develop quickly. This vaccine targets the Bundibugyo virus and promises fast and lasting protection, helping stop outbreaks in Central Africa. Businesses interested in licensing should act soon to bring this life-saving tech to market and can contact NIH for details.
2026-14964, Center for Scientific Review; Notice of Closed Meeting
The Center for Scientific Review is holding a closed virtual meeting on August 19, 2026, to review neuroscience career development grant applications. This meeting is private to protect sensitive info like trade secrets and personal details. Researchers applying for these grants should note the date, as funding decisions could impact their projects and careers.
2026-14848, Prospective Grant of an Exclusive Patent License: RXFP1 AGONISTS
The National Institutes of Health plans to give Modala Bio an exclusive license to use new RXFP1 agonist inventions that could help treat diseases like cancer, heart failure, and fibrosis. This means Modala Bio gets special rights to develop and sell these promising medicines worldwide. If you want to comment or apply for a license, you have until August 24, 2026, so don’t miss out!
Previous / Next Documents
Previous: 2026-12105, Agency Information Collection Activities: Submission for OMB Review; Comment Request
The Centers for Medicare & Medicaid Services (CMS) wants your feedback on their plan to collect some info from the public. This is a routine check to make sure the questions they ask aren’t too much work and actually help them do their job better. If you have thoughts, you’ve got until July 16, 2026, to share them—no cost to you, just your voice!
Next: 2026-12107, Agency Information Collection Request; 30-Day Public Comment Request
The Department of Health and Human Services wants your thoughts on keeping and improving some forms used for applying for federal grants. If you or your organization deals with these grant forms, now’s the time to speak up before July 16, 2026. No big changes or costs are planned—just making sure the forms stay clear and useful!